ornithine has been researched along with trimetrexate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holden, SA; Northey, D; Robinson, MF; Rosowsky, A; Teicher, BA | 1 |
| Assaraf, YG; Dijkmans, BA; Gerards, AH; Jansen, G; Lems, WF; Oerlemans, R; Scheper, RJ; van der Heijden, JW | 1 |
2 other study(ies) available for ornithine and trimetrexate
| Article | Year |
|---|---|
Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Cell Line; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Synergism; Etoposide; Folic Acid Antagonists; Head and Neck Neoplasms; Humans; Male; Methotrexate; Mice; Mice, Inbred C3H; Novobiocin; Ornithine; Pterins; Topoisomerase II Inhibitors; Trimetrexate; Tumor Cells, Cultured | 1995 |
Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Folic Acid Antagonists; Humans; Male; Methotrexate; Middle Aged; Ornithine; Pterins; Quinazolines; T-Lymphocytes; Thiophenes; Trimetrexate; Tumor Necrosis Factor-alpha | 2014 |